Our Partners

At the heart of Open Targets is a consortium of complementary partner institutions that bring their respective expertise to collaborative projects that improve how we systematically identify and prioritise drug targets.

News

Graphic highlighting the liver in the human body, overlayed with data from the publication showing the established human MASLD trajectory based on patient transcriptomic data.

Molecular map of liver disease could transform how MASLD is diagnosed and monitored

14 July 2026

A new study establishes a molecular map of disease progression in Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD), and identifies a set of blood biomarkers that could improve diagnosis.

Summary

  • Scientists mapped the molecular progression of MASLD, uncovering how biological processes driving liver damage change over time, creating a framework for more precise stage-specific therapies.
  • They identified a blood...

    Read more

Read more news about Open Targets

Our Principles

A systematic approach

Systematically identify and prioritise the best targets to safely and effectively treat rare and common diseases

Our scientific approach
Open Exchange of Ideas

We are committed to making our data, methods and results publicly available as soon as possible to foster an open exchange of ideas

Our latest publications
Multidisciplinary collaboration

We believe in non-exclusive partnerships that foster the free exchange of ideas, expertise, and data

Our partners and collaborators

Blog

Origins of the IBDverse: how a conversation in a carpark became one of the largest gut cell studies

Helena Cornu

4 August 2026

Open Targets Platform 26.06 has been released!

Sir Target

24 June 2026

Ensuring stability of the Open Targets Platform: the case for automated end-to-end testing

David Oluwasusi

18 June 2026

Spotlight: Lewis Evans

Helena Cornu, Gosia Trynka

9 June 2026

Shaping Open Targets’ research programme for the next decade

Gosia Trynka, Helena Cornu

9 June 2026

Spotlight: Muzlifah Haniffa

Helena Cornu, Gosia Trynka

9 June 2026

How Open Targets bridges academic science and pharmaceutical expertise

Helena Cornu, Gosia Trynka

9 June 2026

Designing the Perturbation Catalogue—a UX journey through perturbation data

Adedoyin Okunade, Galabina Yordanova

26 May 2026

Visualising complex data in the Open Targets Platform: our design process for Locus-to-Gene scoring representation

Graham McNeill

19 May 2026

From genetic perturbation to drug safety: Sam Moix’s internship at Open Targets

Samuel Moix

14 May 2026

How the Lotfollahi lab created Tripso to interpret single cell data

Helena Cornu

13 April 2026

Integrating Stem Cell Village Models with the Open Targets Platform for drug target discovery

Trevor Atkeson

9 April 2026

Open Targets Platform 26.03 has been released!

Sir Target

23 March 2026

How we improved Locus-to-Gene scoring representation in the Open Targets Platform

Irene López Santiago

24 February 2026

Introducing the official Open Targets Platform Model Context Protocol

David Ochoa

12 January 2026

Open Targets Platform 25.12 has been released!

Sir Target

10 December 2025

Open Targets Platform 25.09 has been released!

Sir Target

17 September 2025

Why Mallory Freeberg is creating a perturbation catalogue

Helena Cornu

23 July 2025

Case study: an Open Targets Platform MCP server

Helena Cornu

17 July 2025

Open Targets Platform 25.06 has been released!

Sir Target

18 June 2025

Bluesky